Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Pittsburgh, Pennsylvania

This page shows live ClinicalTrials.gov search results for Pittsburgh, Pennsylvania, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
10627
Shown on this page
12
Current sort
Recently updated
Location scope
Pittsburgh, PA
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Pittsburgh, Pennsylvania. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 301–312 of 10,627 matching trials in Pittsburgh, PA.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Pittsburgh

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Recruiting Phase 3 Interventional

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

NCT05624450
View directory record Official record
Conditions
Viral Lung Infection and Acute Respiratory Failure
Interventions
Tozorakimab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
3,527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 6, 2026, 6:54 PM EST
Recruiting Phase 3 Interventional

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT06585774
View directory record Official record
Conditions
Chronic Graft-versus-host-disease
Interventions
INCA034176, Placebo, Corticosteroids
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
37
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 6, 2026, 6:54 PM EST
Active, not recruiting Phase 2 Interventional Results available

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

NCT03047135
View directory record Official record
Conditions
Prostate
Interventions
Olaparib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • Omaha, Nebraska • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 6, 2026, 6:54 PM EST
Recruiting Phase 2Phase 3 Interventional

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

NCT05714085
View directory record Official record
Conditions
Heart Failure, Left Ventricular Systolic Dysfunction
Interventions
Vericiguat tablet, Vericiguat suspension, Placebo tablet, Placebo suspension
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
29 Days to 17 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
20
States / cities
Los Angeles, California • Palo Alto, California • San Bernardino, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 6, 2026, 6:54 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

NCT05134974
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle
Drug
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
12 Years and older
Enrollment
368 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
15
States / cities
Newport Beach, California • Westminster, California • Delray Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 6, 2026, 6:54 PM EST
Recruiting Not applicable Interventional

Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT)

NCT05765175
View directory record Official record
Conditions
Tachycardia, Ventricular
Interventions
Varian Cardiac Radioablation (CRA), Catheter Ablation (CA)
Device · Procedure
Lead sponsor
Varian, a Siemens Healthineers Company
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
12
States / cities
Los Angeles, California • Hartford, Connecticut • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 6, 2026, 6:54 PM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia

NCT05646719
View directory record Official record
Conditions
Presbyopia
Interventions
Phentolamine Opthalmic Solution 0.75%, Placebo, Low dose pilocarpine, Low dose pilocarpine vehicle
Drug · Other
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
40 Years to 64 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Azusa, California • Newport Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 6, 2026, 6:54 PM EST
Recruiting Phase 3 Interventional

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06510374
View directory record Official record
Conditions
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Interventions
Nadofaragene Firadenovec
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
55
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 6, 2026, 6:54 PM EST
Recruiting Not applicable Interventional

Risk and Resilience to Suicide Following Late-Life Spousal Bereavement

NCT06191484
View directory record Official record
Conditions
Suicide, Bereavement
Interventions
WELL Behavioral Probe
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 6, 2026, 6:54 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy

NCT06018558
View directory record Official record
Conditions
Geographic Atrophy
Interventions
OCU410
Genetic
Lead sponsor
Ocugen
Industry
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
12
States / cities
Phoenix, Arizona • Coral Springs, Florida • Carmel, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 6, 2026, 6:54 PM EST
Recruiting Phase 3 Interventional

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

NCT06743126
View directory record Official record
Conditions
Melanoma, Cutaneous Malignant, Mucosal Melanoma
Interventions
IMA203, nivolumab plus relatlimab, lifileucel, nivolumab, pembrolizumab, ipilimumab, Dacarbazine, temozolomide, paclitaxel, paclitaxel plus carboplatin, Albumin-Bound Paclitaxel
Biological · Drug
Lead sponsor
Immatics US, Inc.
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
43
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 6, 2026, 6:54 PM EST
Recruiting Phase 2 Interventional

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

NCT06500273
View directory record Official record
Conditions
Large B-cell Lymphoma
Interventions
cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide, Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
Genetic · Drug · Device
Lead sponsor
Allogene Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
64
States / cities
Gilbert, Arizona • Hot Springs, Arkansas • Berkeley, California + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 6, 2026, 6:54 PM EST